NCT01864655View on ClinicalTrials.gov

Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

November 6, 2014

Conditions
Alzheimer's Disease
Interventions
DRUG

saracatinib

oral drug given to experimental group

DRUG

Placebo

Placebo given to placebo group

Trial Locations (1)

06510

Yale Alzheimer's Disease Research Unit, New Haven

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Stephen M. Strittmatter

OTHER

NCT01864655 - Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease | Biotech Hunter | Biotech Hunter